suppressive versus stimulatory effects of allergen/cholera toxoid (ctb) conjugates depending on the nature of the allergen in a murine model of type i allergy.

NLM AIDSLINE Suppressive versus stimulatory effects of allergen/cholera toxoid (CTB) conjugates depending on the nature of the allergen in a murine model of type I allergy. Wiedermann U; Jahn-Schmid B; Lindblad M; Rask C; Holmgren J; Kraft D;
November 30, 1999

Int Immunol. 1999 Jul;11(7):1131-8. Unique Identifier : AIDSLINE Recent reports have demonstrated that feeding small amounts of antigen conjugated to the B subunit of cholera toxin (CTB) suppress immune responses in experimental models of certain Th1-based autoimmune diseases. We have established a model of aerosol sensitization leading to Th2-mediated allergic immune responses in BALB/c mice. In the present study two different antigens, the dietary antigen ovalbumin (OVA) and the inhalant allergen Bet v 1 (the major birch pollen allergen), chemically coupled to recombinant CTB were tested for their potential to influence Th2-like immune responses. Intranasal administration of OVA-CTB prior to sensitization with OVA led to a significant decrease of antigen-specific IgE antibody levels, but a marked increase of OVA-specific IgG2a antibodies as compared to non-pretreated, sensitized animals. Antigen-specific lympho-proliferative responses in vitro were reduced by 65% in the pretreated group; IL-5 and IL-4, but not IFN-gamma, production were markedly decreased in responder cells of lungs and spleens of nasally pretreated mice. In contrast, mucosal administration of rBet v 1-CTB conjugates prior to sensitization led to an up-regulation of allergen-specific IgE, IgG1 and IgG2a, increased in vitro lympho-proliferative responses as well as augmented production of IL-5, IL-4, IL-10 and IFN-gamma. Intranasal administration prior to sensitization of unconjugated allergens showed also contrasting effects: OVA could not significantly influence antigen-specific antibody or cytokine production, whereas intranasal pretreatment with unconjugated Bet v 1 suppressed allergen-specific immune responses in vivo and in vitro. These results demonstrated that the two antigens--in conjugated as in unconjugated form--had different effects on the Th2 immune responses. We therefore conclude that the tolerogenic or immunogenic properties of CTB--and probably also other antigen-delivery systems--strongly depend on the nature of the coupled antigen-allergen. JOURNAL ARTICLE Adjuvants, Immunologic/ADMINISTRATION & DOSAGE Administration, Intranasal Animal Comparative Study Cytokines/BIOSYNTHESIS Desensitization, Immunologic Disease Models, Animal Female Hypersensitivity, Immediate/IMMUNOLOGY/METABOLISM/THERAPY Immunity, Mucosal/IMMUNOLOGY Immunoconjugates/IMMUNOLOGY Interleukin-4/BIOSYNTHESIS Interleukin-5/BIOSYNTHESIS Lymphocyte Transformation/IMMUNOLOGY Mice Mice, Inbred BALB C Ovalbumin/IMMUNOLOGY Plant Proteins/IMMUNOLOGY Support, Non-U.S. Gov't Th2 Cells/IMMUNOLOGY Toxoids/*IMMUNOLOGY

Most Read: Latest Added Related Topics White House LGBT Conference on HIV/AIDS UNITED STATES: White House in Atlanta: LGBT AIDS Conference No more single-theme conferences: global HIV prevention conference planned FHI 360 Senior Scientist Lut Van Damme Receives International Microbicide Conference Lifetime Achievement Award Equatorial Guinea Ministry of Health and Social Welfare and UNICEF Refute Erroneous AIDS Prevalence Figures Photographs from A Day with HIV Now Online Bulgaria urges Libya to investigate AIDS nurses case Engineers enter fight against AIDS in Africa Gilead’s Complera® Non-Inferior to Atripla® Among Treatment-Naive HIV Patients UN chief Ban calls world leaders to end Aids by 2020 COLORADO: Boulder Groups Honor More Than 150 Local AIDS Victims PENNSYLVANIA: Area Residents Screened for Hepatitis C on Sunday COLORADO: Peer to Peer: Teens Work to Educate Peers on Pregnancy, STDs at CCHS OREGON: Portland Barefoot 3 x 3 Benefit Tournament to Draw Hundreds to Northeast Portland TEXAS: Temple - Wellness and Sexual Health Classes Helping Kids to Abstain CONNECTICUT: Yale Researchers Urge More Street Work When Studying People With Both HIV, Hepatitis C JAMAICA: AIDS Awareness Workshop Organised for High-School Students EUROPE: EU Issues Stringent Sharps Regulations CALIFORNIA: $50,000 Prisoner Prescription: Inmates Get Expensive Hepatitis C Treatment Tentative approval of lamivudine and tenofovir disoproxil fumarate Tablets, 300 mg/300 mg UNITED STATES: Triple Therapy for Hepatitis C is Effective After Liver Transplantation, but Side-Effects Are Common 2012 US medicine sales show shifts by drug type Unwelcome side effects of mining in Mozambique Global Fund announces first new grants under new model Drug interaction warning for hepatitis C: serious side effects when using telaprevir and bosentan UNITED STATES: Long-term Effects Similar for Two-, Three-dose Regimens of Hepatitis A Vaccine New Superiority Trial Showed LIVALO® pitavastatin 4 mg Provided Significantly Greater LDL-C Reduction in HIV-Infected Adults with Dyslipidemia versus Pravastatin 40 mg New Superiority Trial Showed LIVALO(R) (pitavastatin) 4 mg Provided Significantly Greater LDL-C Reduction in HIV-Infected Adults with Dyslipidemia versus Pravastatin 40 mg: Study results presented as late-breaker at CROI 2013 this week The Global Fund launches new funding model to support countries in responding to HIV, TB and malaria Global Fund Launches New Funding Model
Information in this article was accurate in November 30, 1999. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.